Aerie Pharmaceuticals Stock Forecast, Price & News

Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AERI stock has decreased by 31.9% and is now trading at $9.91.
View which stocks have been most impacted by COVID-19.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 2 sell ratings, 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aerie Pharmaceuticals.

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Aerie Pharmaceuticals.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released its earnings results on Thursday, August, 6th. The company reported ($0.83) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.79) by $0.04. The firm earned $18.03 million during the quarter, compared to analyst estimates of $18.65 million. Aerie Pharmaceuticals had a negative return on equity of 107.42% and a negative net margin of 247.36%.
View Aerie Pharmaceuticals' earnings history.

15 equities research analysts have issued 1-year price targets for Aerie Pharmaceuticals' stock. Their forecasts range from $9.00 to $50.00. On average, they expect Aerie Pharmaceuticals' stock price to reach $27.29 in the next twelve months. This suggests a possible upside of 175.3% from the stock's current price.
View analysts' price targets for Aerie Pharmaceuticals.

Some companies that are related to Aerie Pharmaceuticals include Replimune Group (REPL), Bavarian Nordic A/S (BVNRY), AlloVir (ALVR), Kymera Therapeutics (KYMR), Sangamo Therapeutics (SGMO), Cortexyme (CRTX), NanoString Technologies (NSTG), Mesoblast (MESO), Coherus Biosciences (CHRS), I-Mab (BDTX), Atara Biotherapeutics (ATRA), REGENXBIO (RGNX), Translate Bio (TBIO), Adverum Biotechnologies (ADVM) and Compugen (CGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Canopy Growth (CGC), Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Aerie Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (1.83%), Pinnacle Associates Ltd. (1.13%), CWM LLC (0.45%), Envestnet Asset Management Inc. (0.12%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino and Vicente Anido Jr.
View institutional ownership trends for Aerie Pharmaceuticals.

AERI stock was sold by a variety of institutional investors in the last quarter, including CWM LLC, and Pinnacle Associates Ltd..
View insider buying and selling activity for Aerie Pharmaceuticals.

AERI stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Envestnet Asset Management Inc., and Nisa Investment Advisors LLC. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino, and Vicente Anido Jr.
View insider buying and selling activity for Aerie Pharmaceuticals.

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AERI stock can currently be purchased for approximately $9.91.

Aerie Pharmaceuticals has a market capitalization of $460.95 million and generates $69.89 million in revenue each year. The company earns $-199,580,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Aerie Pharmaceuticals employs 380 workers across the globe.

The official website for Aerie Pharmaceuticals is www.aeriepharma.com.

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]